📊 SRRK Key Takeaways
Is Scholar Rock Holding Corp (SRRK) a Good Investment?
Scholar Rock is a pre-revenue biotech company with zero commercial revenue and -$105.5M net losses, burning ~$82M in cash per quarter. While the $430.5M cash position provides ~1.3 years of runway, the fundamental metrics indicate an unsustainable business model dependent entirely on future drug approvals and commercialization success, which remains highly speculative.
Scholar Rock Holding Corp Key Strengths (SRRK)
- Strong cash position of $430.5M relative to $259.2M liabilities provides meaningful runway for development
- Excellent liquidity metrics with 8.64x current ratio indicates ability to meet near-term obligations
- Conservative capital structure with 0.71x Debt/Equity ratio limits financial distress risk
SRRK Stock Risks: Scholar Rock Holding Corp Investment Risks
- Zero revenue with -100% YoY decline reflects complete absence of commercial products or market traction
- Operating losses of -$102M and net losses of -$105.5M demonstrate fundamentally unprofitable operations
- Quarterly cash burn of ~$82M limits runway to approximately 1.3 years at current burn rate without revenue generation or funding
- Negative operating cash flow of -$82.1M and negative ROE (-38.2%) indicate unsustainable economics
- Binary risk profile as pre-revenue biotech dependent on clinical trial success and regulatory approvals
Key Metrics to Watch
- Revenue generation and commercialization milestones for pipeline drugs
- Quarterly cash burn rate and projected runway to profitability or next funding event
- Clinical trial results and regulatory approval progress for development programs
Scholar Rock Holding Corp (SRRK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.64x current ratio provides a solid financial cushion.
SRRK Profit Margin, ROE & Profitability Analysis
SRRK vs Healthcare Sector: How Scholar Rock Holding Corp Compares
How Scholar Rock Holding Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Scholar Rock Holding Corp Stock Overvalued? SRRK Valuation Analysis 2026
Based on fundamental analysis, Scholar Rock Holding Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Scholar Rock Holding Corp Balance Sheet: SRRK Debt, Cash & Liquidity
SRRK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Scholar Rock Holding Corp's revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-2.47 indicates the company is currently unprofitable.
SRRK Revenue Growth, EPS Growth & YoY Performance
SRRK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$74.7M | $-0.67 |
| Q3 2025 | N/A | -$56.9M | $-0.66 |
| Q2 2025 | N/A | -$56.9M | $-0.60 |
| Q3 2023 | $33.2M | -$8.0M | $-0.53 |
| Q2 2023 | $33.2M | -$8.0M | $-0.47 |
| Q1 2023 | $33.2M | -$8.0M | $-0.21 |
| Q3 2022 | $5.5M | -$8.0M | $-0.55 |
| Q2 2022 | $4.6M | -$8.0M | $-0.84 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Scholar Rock Holding Corp Dividends, Buybacks & Capital Allocation
SRRK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Scholar Rock Holding Corp (CIK: 0001727196)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SRRK
What is the AI rating for SRRK?
Scholar Rock Holding Corp (SRRK) has an AI grade of C with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SRRK's key strengths?
Claude: Strong cash position of $430.5M relative to $259.2M liabilities provides meaningful runway for development. Excellent liquidity metrics with 8.64x current ratio indicates ability to meet near-term obligations.
What are the risks of investing in SRRK?
Claude: Zero revenue with -100% YoY decline reflects complete absence of commercial products or market traction. Operating losses of -$102M and net losses of -$105.5M demonstrate fundamentally unprofitable operations.
What is SRRK's revenue and growth?
Scholar Rock Holding Corp reported revenue of $0.0.
Does SRRK pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
Where can I find SRRK SEC filings?
Official SEC filings for Scholar Rock Holding Corp (CIK: 0001727196) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SRRK's EPS?
Scholar Rock Holding Corp has a diluted EPS of $-0.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SRRK's fundamental grade?
Based on our AI fundamental analysis in June 2026, Scholar Rock Holding Corp has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SRRK stock overvalued or undervalued?
Valuation metrics for SRRK: ROE of -38.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SRRK's AI grade for 2026?
Our dual AI analysis gives Scholar Rock Holding Corp a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SRRK's free cash flow?
Scholar Rock Holding Corp's operating cash flow is $-82.1M, with capital expenditures of $68.0K.
How does SRRK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -38.2% (avg: 15%), current ratio 8.64 (avg: 2).